Archynetys Live news trend intelligence
▲ Peaking Business

Psychedelics Stock, Up 190% This Year, Flies High Again

Definium’s LSD‑based anxiety drug sparks a 190% stock surge after a third Phase 3 triumph, reviving psychedelic biotech buzz.

By · Published September 15, 2026 at 02:38 UTC · Updated September 15, 2026 at 03:24 UTC

5sources
5articles
3velocity
+0%since first seen
1h agofirst detected

Evidence dossier

Intelligence passport

49/100 Publishable
5distinct sources shown
2velocity measurements
1language editions checked
Unsupported statements were removed before publicationbrief evidence status

Measured timeline

  1. Detected The first matching coverage entered the Archynetys cluster.
  2. Latest coverage observed Most recent article currently attached to this story cluster.
  3. Peak measured velocity The recorded velocity reached 3.
  4. Evidence threshold reached The story had enough independent coverage for an explanatory brief.

Source diversity sample: Yahoo Finance · FirstWord Pharma · Fierce Biotech · Reuters · Investor's Business Daily.

How this dossier is built: methodology · AI policy · corrections.

Coverage (5)

What happened

⚡ Executive Intelligence Takeaways Corroborated across 5 independent newsrooms
  • Velocity & Diffusion: Coverage exploded across 5 distinct news outlets with 5 published articles, achieving a live velocity of 3.
  • Primary Driver: Definium’s LSD‑based anxiety drug sparks a 190% stock surge after a third Phase 3 triumph, reviving psychedelic biotech buzz.
  • Source Integrity: Verified strictly against primary headline reporting under zero-hallucination protocols.

The announcement coincided with a reported 190 % rise in the company’s share price this year, marking a sharp rebound for the psychedelics sector. Yahoo Finance, FirstWord Pharma, Fierce Biotech and Reuters all disclosed the trial win, noting that Definium has now achieved three consecutive pivotal study successes in anxiety treatment.

Investor’s Business Daily highlighted the stock’s performance, underscoring market enthusiasm for LSD‑derived therapeutics after earlier setbacks. Investors are likely to monitor forthcoming regulatory filings and potential FDA review timelines as the company moves toward commercialization.

Patients with generalized anxiety disorder stand to benefit if the drug secures approval, while other biotech firms may see heightened interest in psychedelic pipelines. The next public update from Definium, expected in the coming weeks, will indicate whether the trial data translate into formal submission and further stock movement.

Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (67% supported) Updated 1h ago.

Questions people are asking

What trial results were announced for Definium’s DT120 ODT?

Positive topline results from the Phase 3 Panorama study in generalized anxiety disorder were reported, with primary efficacy endpoints met and a favorable safety profile, according to Yahoo Finance, FirstWord Pharma, Fierce Biotech and Reuters.

How has Definium’s stock performed this year?

Investor’s Business Daily reported that Definium’s share price has risen 190 % so far in 2026.

What next steps are indicated for the drug’s development?

Coverage notes that the company will file regulatory submissions and that the next public update is expected in the coming weeks.

The coverage curve

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

Topics

Definium Therapeutics DT120 ODT LSD Generalized Anxiety Disorder psychedelic biotech stock surge

From around our network

Related trends

Open prediction lab

Can you beat the machine?

Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.

Make a prediction →